Molecular and Serological Prevalence of HCMV in Iranian Patients with Breast Cancer.
Breast Neoplasms
Cytomegalovirus
Iran
Prevalence
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Jul 2021
01 Jul 2021
Historique:
received:
19
12
2020
entrez:
28
7
2021
pubmed:
29
7
2021
medline:
30
12
2021
Statut:
epublish
Résumé
Human cytomegalovirus (HCMV) is prevalent viral infection involved in several human cancers including breast cancer. The presence of HCMV genome in breast cancer tissue and footprint of viral last exposure patient's serum are considered as important factor in the process of breast cancer development. This study aimed to investigate molecular and serological epidemiology of HCMV in patients with breast cancer in Iran for first time. In our case-control study, 98 samples of breast tissue, including 49 cancerous (case) and 49 adjacent non-cancerous tissue were collected (control). In addition, we collected sera samples from all patients (n=49) and healthy individual (n=49). Seroprevalence of HCMV was assessed by Enzyme-linked immunosorbent assay (ELISA) and detection of HCMV genome was performed using Nested-PCR method. HCMV genome found in 16.3% (8/49) of cases tissue and 2% (1/49) of controls tissue. In patients group, the levels of anti-CMV IgG and IgM were 93.9% and 2% compared to 69.4% and 4.1% in healthy individuals, respectively. There was a statistically difference between the anti-CMV IgG in patients and healthy control (p= 0.002). We found 75% of (6/8) HCMV genome positive PCR samples were also positive for their anti-CMV IgG in cases which was statistically significant (p= 0.01). Conclusions: Our result showed significant presence of HCMV genome and anti-CMV IgG in patients, supporting the role of HCMV in breast cancer.<br />.
Sections du résumé
BACKGROUND
BACKGROUND
Human cytomegalovirus (HCMV) is prevalent viral infection involved in several human cancers including breast cancer. The presence of HCMV genome in breast cancer tissue and footprint of viral last exposure patient's serum are considered as important factor in the process of breast cancer development.
OBJECTIVES
OBJECTIVE
This study aimed to investigate molecular and serological epidemiology of HCMV in patients with breast cancer in Iran for first time.
METHODS
METHODS
In our case-control study, 98 samples of breast tissue, including 49 cancerous (case) and 49 adjacent non-cancerous tissue were collected (control). In addition, we collected sera samples from all patients (n=49) and healthy individual (n=49). Seroprevalence of HCMV was assessed by Enzyme-linked immunosorbent assay (ELISA) and detection of HCMV genome was performed using Nested-PCR method.
RESULTS
RESULTS
HCMV genome found in 16.3% (8/49) of cases tissue and 2% (1/49) of controls tissue. In patients group, the levels of anti-CMV IgG and IgM were 93.9% and 2% compared to 69.4% and 4.1% in healthy individuals, respectively. There was a statistically difference between the anti-CMV IgG in patients and healthy control (p= 0.002). We found 75% of (6/8) HCMV genome positive PCR samples were also positive for their anti-CMV IgG in cases which was statistically significant (p= 0.01). Conclusions: Our result showed significant presence of HCMV genome and anti-CMV IgG in patients, supporting the role of HCMV in breast cancer.<br />.
Identifiants
pubmed: 34319021
doi: 10.31557/APJCP.2021.22.7.2011
pmc: PMC8607108
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2011-2016Références
Asian Pac J Cancer Prev. 2017 Dec 29;18(12):3319-3324
pubmed: 29286226
Herpesviridae. 2010 Dec 23;1(1):8
pubmed: 21429243
Asian Pac J Cancer Prev. 2019 Aug 01;20(8):2275-2279
pubmed: 31450895
Rev Med Virol. 2010 Jul;20(4):202-13
pubmed: 20564615
Oncotarget. 2019 Jul 02;10(42):4333-4347
pubmed: 31303966
Rev Med Virol. 2019 May;29(3):e2034
pubmed: 30706584
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Iran J Public Health. 2019 Feb;48(2):206-216
pubmed: 31205874
Breast Cancer (Dove Med Press). 2019 Apr 10;11:151-164
pubmed: 31040712
Cancers (Basel). 2019 Nov 22;11(12):
pubmed: 31766600
PLoS One. 2015 Feb 27;10(2):e0118989
pubmed: 25723522
Neoplasia. 2009 Jan;11(1):1-9
pubmed: 19107226
Breast Cancer Res. 2010;12(4):207
pubmed: 20804570
Cancer Epidemiol Biomarkers Prev. 2001 Jan;10(1):9-16
pubmed: 11205495
Int J Reprod Biomed. 2020 Jul 22;18(7):501-508
pubmed: 32803115
J Adv Pharm Technol Res. 2010 Apr;1(2):109-26
pubmed: 22247839
Med Hypotheses. 1997 Jun;48(6):491-7
pubmed: 9247892
J Natl Cancer Inst. 2000 Jul 19;92(14):1126-35
pubmed: 10904085
Clin Breast Cancer. 2018 Aug;18(4):e629-e642
pubmed: 29396078
Br J Cancer. 2005 Oct 31;93(9):1046-52
pubmed: 16175185
Br J Cancer. 2004 Jun 1;90(11):2149-52
pubmed: 15150559
Br J Cancer. 2010 May 25;102(11):1665-9
pubmed: 20407437
Infect Agent Cancer. 2017 Jun 26;12:39
pubmed: 28670334
Infect Genet Evol. 2020 Dec;86:104603
pubmed: 33091575
Iran J Public Health. 2012;41(11):1-9
pubmed: 23304670
Infect Agent Cancer. 2013 Sep 02;8:32
pubmed: 24138789